EXAMINE THIS REPORT ON HEMGENIX

Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of sufferers with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are labeled as possessing gentle or moderate disease can have a critical bleeding